Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19).

The SARS-CoV-2 virus spreading across the world has led to surges of COVID-19 illness, hospitalizations, and death. The complex and multifaceted pathophysiology of life-threatening COVID-19 illness including viral mediated organ damage, cytokine storm, and thrombosis warrants early interventions to address all components of the devastating illness. In countries where therapeutic nihilism is prevalent, patients endure escalating symptoms and without early treatment can succumb to delayed in-hospital care and death.

Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.

Background: Thromboembolic events are occurring at increasing rates in neonates and infants. At Children's Mercy Hospitals and Clinics, antithrombin III (AT3) concentrates are often used in combination with enoxaparin to supplement physiologically low AT3 levels. Theoretically, AT3 enhances the anticoagulant activity of enoxaparin and results in decreased time to therapeutic anti-Xa levels.

Caregiver survey results related to handling of oral chemotherapy for pediatric patients with acute lymphoblastic leukemia.

Background: Oral chemotherapy is commonly administered in the home; however, there may be harmful effects on healthy individuals who handle these medications. Caregivers of pediatric patients were surveyed to establish educational needs for safe handling of oral chemotherapy agents.

Methods: An 11-question self-report survey was developed to characterize handling practices for patients in maintenance therapy for acute lymphoblastic leukemia related to caregiver education, use of protective gear, preparation, and disposal of oral chemotherapy agents.